Literature DB >> 2574068

The nature and prevalence of depression in chronic schizophrenic in-patients.

T R Barnes1, D A Curson, P F Liddle, M Patel.   

Abstract

Out of 194 chronic schizophrenic in-patients, depressed mood (item 23 of the PSE) was present in 25 (13%). When compared with 25 matched controls, the patients with depressed mood had significantly higher scores on the MADRS and the Beck Depression Inventory. Serious suicidal ideas and auditory hallucinations were significantly more common in the depressed group. However, there were no significant differences between the matched groups in terms of negative symptoms, Parkinsonism, tardive dyskinesia, anticholinergic medication, or current dose of antipsychotic drug, which suggests that the depression identified was not related to drug treatment, nor was it a direct manifestation or misinterpretation of negative symptoms. Over three-month follow-up, the MADRS and Beck scores covaried closely with the presence or absence of depressed mood. This depressive syndrome persisted over the three months in the majority of patients originally depressed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2574068     DOI: 10.1192/bjp.154.4.486

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  22 in total

1.  The burden of depressive symptoms in the long-term treatment of patients with schizophrenia.

Authors:  Robert R Conley; Haya Ascher-Svanum; Baojin Zhu; Douglas E Faries; Bruce J Kinon
Journal:  Schizophr Res       Date:  2006-11-15       Impact factor: 4.939

2.  Component structure of the expanded Brief Psychiatric Rating Scale (BPRS-E).

Authors:  P M Dingemans; D H Linszen; M E Lenior; R M Smeets
Journal:  Psychopharmacology (Berl)       Date:  1995-12       Impact factor: 4.530

3.  Negative symptoms and their association with depressive symptoms in the long-term course of schizophrenia.

Authors:  Wolfram An der Heiden; Anne Leber; Heinz Häfner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-04-23       Impact factor: 5.270

4.  Depression in the long-term course of schizophrenia.

Authors:  Wolfram an der Heiden; Regina Könnecke; Kurt Maurer; Daniel Ropeter; Heinz Häfner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-06       Impact factor: 5.270

Review 5.  Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes.

Authors:  W W Fleischhacker; M Hummer
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

6.  Comorbidity in Schizophrenia: Conceptual Issues and Clinical Management.

Authors:  Hussain Muhammad Abdullah; Hameed Azeb Shahul; Michael Y Hwang; Stephen Ferrando
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-11-05

Review 7.  First-episode schizophrenia: a focus on pharmacological treatment and safety considerations.

Authors:  Deanna L Kelly; Robert R Conley; William T Carpenter
Journal:  Drugs       Date:  2005       Impact factor: 9.546

8.  Chronic administration of atypical antipsychotics improves behavioral and synaptic defects of STOP null mice.

Authors:  David Delotterie; Geoffrey Ruiz; Jacques Brocard; Annie Schweitzer; Corinne Roucard; Yann Roche; Marie-Françoise Suaud-Chagny; Karine Bressand; Annie Andrieux
Journal:  Psychopharmacology (Berl)       Date:  2009-11-21       Impact factor: 4.530

9.  Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia.

Authors:  Y Noda; K Yamada; H Furukawa; T Nabeshima
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

10.  Inner connections within domain of dementia praecox: role of supervisory mental processes in schizophrenia.

Authors:  P F Liddle
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.